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OBJECTIVES The purpose of this study was to estimate the frequency of NKX2.5 mutations in specific
cardiovascular anomalies and investigate genotype-phenotype correlations in individuals with
NKX2.5 mutations.
BACKGROUND Recent reports have implicated mutations in the transcription factor NKX2.5 as a cause of
various congenital heart defects (CHD).
METHODS We tested genomic deoxyribonucleic acid from 608 prospectively recruited patients with
conotruncal anomalies (n  370), left-sided lesions (n  160), secundum atrial septal
defect (ASD) (n  71), and Ebstein’s malformation (n  7) for NKX2.5 mutations.
RESULTS Twelve distinct mutations in the NKX2.5 coding region were identified in 18 of 608 patients
(3%), including 9 of 201 (4%) with tetralogy of Fallot, 3 of 71 (4%) with a secundum ASD,
one each with truncus arteriosus, double-outlet right ventricle, L-transposition of the great
arteries, interrupted aortic arch, hypoplastic left heart syndrome, and aortic coarctation, but
in no patients with D-transposition of the great arteries (n  86) or valvar aortic stenosis (n
 21). Eleven of the mutations were amino acid-altering missense nucleotide substitutions or
deletions, and one was predicted to cause premature termination of translation. None of the
mutations were in the homeodomain. Sixteen of the 18 individuals with NKX2.5 mutations
in this study had no family history of congenital cardiovascular anomalies, and one had
first-degree atrioventricular (AV) block.
CONCLUSIONS NKX2.5 mutations occur in a small percentage of patients with various CHD. Most of the
mutations identified in this study were missense, outside the homeodomain, and not
associated with AV block. These findings suggest that NKX2.5 mutations in non-
homeodomain regions may be important in the development of human structural cardiac
defects. (J Am Coll Cardiol 2003;42:1650–5) © 2003 by the American College of
Cardiology Foundation
GENETICS IN CONTEXT
Focus on gene mutations in congenital heart disease. Although congenital
heart defects (CHD) are the leading cause of morbidity and mortality in
infants, the etiology of most CHD remains unknown, with the influence of
genetics still a topic of debate. The increased recurrence risk for parents with
an affected child suggests the potential for inherited predisposing mutations
that are incompletely penetrant.
Heterozygous mutations in the transcription factor, NKX2-5, were among
the first evidence of a genetic cause for congenital heart disease and were
initially found in pedigrees with autosomal dominant transmission of
cardiac septal defects. Most reported NKX2-5 mutations were in the
homeodomain, a critical part of the protein that interacts with deoxyribo-
nucleic acid (DNA), and were typically associated with cardiac conduction
anomalies. However, the impact of NKX2-5 mutations on “sporadic” forms
of isolated CHD in a broad population was unknown. In this study by
McElhinney et al., 608 children with a variety of non-familial CHD, but
normal conduction, were studied for mutations in NKX2-5. Three percent
of the entire cohort, a relatively large number for a single gene, had
mutations that did not appear to be polymorphisms. Interestingly, none were
in the critical homeodomain, suggesting that other protein domains likely
affect specific developmental processes without disrupting development of the
conduction system.
It remains intriguing that disruption of a single gene can cause the diverse
forms of CHD described here. This could be attributed to specific roles of
distinct regions of the NKX2-5 protein or simply the presence of other
stochastic events. Finally, the notion of CHD as an inherited disorder with
incomplete penetrance is supported by the common identification of an
NKX2-5 point mutation in a normal parent. Similar analyses for other
critical genes may together begin to establish a genetic basis for most
“sporadic” forms of CHD. This effort will lay the foundation for more
accurate genetic counseling, clinical interventions, and most importantly,
new approaches for prevention of CHD in those who are genetically
susceptible.
—Deepak Srivastava
University of Texas Southwestern Medical Center
Dallas, Texas
From *The Children’s Hospital of Philadelphia and University of Pennsylvania
School of Medicine, Philadelphia, Pennsylvania; and †Children’s Hospital Medical
Center, Cincinnati, Ohio. Supported by the National Institutes of Health (P50
HL62177 [E.G.] and P50 HL61006 [D.W.B.]), The Ethel Brown Foerderer Fund
for Excellence (E.G.), The University of Pennsylvania Research Foundation (E.G.),
and the General Clinical Research Center of The Children’s Hospital of Philadelphia
(M01-RR00240 [E.G.]). Present address for Dr. McElhinney: Department of
Cardiology, Children’s Hospital, Boston, Massachusetts.
Manuscript received December 11, 2002; revised manuscript received March 18,
2003, accepted May 30, 2003.
Journal of the American College of Cardiology Vol. 42, No. 9, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)01082-9
Mutations of NKX2.5, primarily in the homeodomain, have
been identified in at least 11 kindreds with atrioventricular
(AV) conduction block and concurrent congenital heart
malformations, including secundum atrial septal defect
(ASD) and tetralogy of Fallot (Table 1) (1–3). For this
reason, we genotyped prospectively recruited patients with
tetralogy of Fallot for NKX2.5 and identified four missense
mutations in six of the 114 patients (5%) (4). All of these
mutations were outside of the homeodomain and in indi-
viduals without AV conduction abnormalities, as was the
case in one previously reported patient with tetralogy of
Fallot and an NKX2.5 mutation (2). To investigate further
the genotype-phenotype correlation in patients with con-
genital heart disease and an NKX2.5 mutation, and to
estimate the frequency of NKX2.5 mutations in individuals
with specific congenital cardiovascular anomalies, we geno-
typed 608 prospectively recruited patients with congenital
heart disease by conformation-sensitive gel electrophoresis
(CSGE) and/or direct sequencing. In contrast to earlier
studies, which ascertained subjects on the basis of familial
congenital heart disease (1–3), the subjects in this report
were enrolled on the basis of specific cardiovascular pheno-
types without regard for family history or the presence of
AV conduction abnormalities.
METHODS
Patients. Genotype data from a total of 608 subjects are
summarized for this report. Genomic deoxyribonucleic acid
(DNA) from 474 new subjects with conotruncal cardiovas-
cular anomalies (n  236), left-sided lesions (n  160),
secundum ASD (n  71), and Ebstein’s malformation (n 
7) were tested for mutations in the coding region of
NKX2.5. Conotruncal anomalies included new patients
with tetralogy of Fallot (n  67), D-transposition of the
great arteries (n  86), double-outlet right ventricle (n 
31), interrupted aortic arch (n  23), truncus arteriosus (n
 22), and L-transposition of the great arteries (n  7).
Left-sided lesions included hypoplastic left heart syndrome
(n  80), coarctation of the aorta (n  59), and valvar aortic
stenosis (n  21). To estimate frequency, we included the
134 patients with tetralogy of Fallot previously studied in
our laboratories and reported earlier, given that they were
enrolled in the same protocols as the other subjects (2,4).
Therefore, the total number of patients described in this
report is 608.
Subjects were drawn from a cohort of patients that were
recruited prospectively into studies on the genetic basis of
congenital heart disease from 1991 to 2001. Informed
consent was obtained from study participants in accordance
with protocols approved by the Institutional Review Board
for Human Research at the Children’s Hospital of Phila-
delphia or the Medical University of South Carolina. All
subjects with conotruncal malformations were tested for a
chromosome 22q11 deletion as previously described (5).
Some patients underwent other cytogenetic testing if clin-
ically indicated. Patients were invited to enroll in the
aforementioned studies after admission to the hospital,
exclusively on the basis of the CHD present in the proband,
with no selection for or against familial congenital heart
disease or syndromic associations. However, patients with a
chromosome 22q11 deletion, trisomy 21, or other identified
chromosomal anomaly were excluded from the present
analysis. Cardiovascular diagnoses were confirmed by at-
tending pediatric cardiologists (E.G. and D.W.B.), who
reviewed echocardiograms and/or echocardiogram reports,
cardiac catheterization reports, and operative notes if appli-
cable. Electrocardiograms were reviewed for abnormalities
Abbreviations and Acronyms
ASD  atrial septal defect
AV  atrioventricular
CHD  congenital heart defect
CSGE  conformation-sensitive gel electrophoresis
DNA  deoxyribonucleic acid
PCR  polymerase chain reaction
Table 1. Previously Reported NKX2.5 Mutations*
Mutation Site # Patients # With AVB # With ASD
# With
Other CHD
Int 1DSG  1T Splice site 1 1 0 0
C554T (Gln149ter) Homeodomain 6 5 4 3-TOF, VSD
C618T (Gln170ter) Homeodomain 4 4 2 0
C642T (Thr178Met)† Homeodomain 12 12 11 0‡
C673A (Asn188Cys) Homeodomain 5 5 5 3-TV anomaly§
C674G (Arg189Gly) Homeodomain 5 5 4 1-TV anomaly
A681G (Tyr191Cys) Homeodomain 1 1 1 1-VSD
C701T (Gln198ter)† 3 coding region 4 4 4 0
C886A (Tyr259ter) 3 coding region 7 7 6 3-DORV, VSD
Total 45 44 (98%) 37 (82%) 11 (24%)
*Includes the reports of Schott et al (1), Hosoda et al. (3), and Benson et al. (2), although the 20 patients with sporadic tetralogy
of Fallot in the report by Benson et al., who are included in the current study, are excluded from this table. Patients reported
by Goldmuntz et al. (4); who are included in the current study, are excluded from this table as well. †Two separate families have
been reported with these mutations. ‡One of the two families with this mutation included four members who were not genotyped
but had tetralogy of Fallot (n  2) or a ventricular septal defect (n  2). §All three of these patients had Ebstein’s malformation.
ASD  secundum atrial septal defect; AVB  atrioventricular block; CHD  congenital heart defects; DORV 
double-outlet right ventricle; TOF  tetralogy of Fallot; TV  tricuspid valve; VSD  ventricular septal defect.
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of AV conduction in all patients with secundum ASD and
Ebstein’s malformation, as well as those with other anom-
alies who were found to have an NKX2.5 mutation. Family
history of congenital heart disease was ascertained by report
(i.e., clinical testing of parents was not performed for the
purposes of this study), and an effort was made to obtain
parental DNA for mutation analysis in all patients found to
have an NKX2.5 mutation. Medical records of patients with
an NKX2.5 mutation were reviewed to determine whether
any non-cardiac congenital malformations or recognized
genetic syndrome was present.
Genotype analysis. Deoxyribonucleic acid was extracted
from either whole blood or a lymphoblastoid cell line using
standard techniques. The coding region of the NKX2.5
gene, including exon/intron boundaries, was amplified from
genomic DNA by polymerase chain reaction (PCR) using
standard techniques, as described previously (4). The PCR
products were screened for sequence alterations either by
CSGE, a modification of heteroduplex analysis (6), as
described previously (4), or by direct sequencing. The PCR
products were directly sequenced in certain cohorts (e.g., all
patients with tetralogy of Fallot, Ebstein’s malformation, or
an ASD) and in selected patients with other diagnoses. The
remaining patients were evaluated initially by CSGE, and in
those with an aberrant band on the CSGE gel, the shifted
region of the gene was subsequently sequenced with an
automated cycle sequencer (ABI Prism 373 or 377 Se-
quencer, ABI BigDye Terminator Cycle Sequencing Kit,
Applied Biosystems, Foster City, California), as described
previously (4). Among the 608 patients, the NKX2.5 coding
region was sequenced in its entirety in 316 (52%) and
partially in 80 (13%). Sequence alterations were examined in
the context of the open reading frame to determine whether
they would alter the corresponding amino acid.
RESULTS
Twelve distinct mutations in the coding region of NKX2.5
were identified in 18 of the 608 (3%) probands evaluated.
Four mutations in seven of these subjects were previously
reported (2,4) but are included in this report to allow for
estimation of frequency, as previously noted. The cardio-
vascular anomalies in the individuals tested and affected are
summarized in Table 2. The details of the specific muta-
tions are summarized in Table 3.
Among patients with conotruncal anomalies, NKX2.5
mutations were detected in 13 patients, including 9 of 201
patients with tetralogy of Fallot (4%), and one each with
truncus arteriosus, double-outlet right ventricle, interrupted
aortic arch, and L-transposition of the great arteries. Nota-
bly, mutations were found among the 86 patients with
Table 2. Frequency of NKX2.5 Mutations Among 608 Patients
With Congenital Heart Disease
Cardiovascular Anomaly
# Patients
Genotyped
# With
Mutations
Secundum atrial septal defect 71 3 (4%)
Ebstein’s malformation 7 0
Conotruncal anomalies
Tetralogy of Fallot* 201 9 (4%)
D-transposition of the great arteries 86 0
Double-outlet right ventricle 31 1 (3%)
Interrupted aortic arch 23 1 (4%)
Truncus arteriosus 22 1 (4%)
L-transposition of the great arteries 7 1 (14%)
Subtotal (conotruncal anomalies) 370 13 (4%)
Left-sided lesions
Hypoplastic left heart syndrome 80 1 (1%)
Coarctation of the aorta 59 1 (2%)
Valvar aortic stenosis 21 0
Subtotal (left-sided lesions) 160 2 (2%)
Total 608 18 (3%)
*Includes 134 consecutively recruited patients with tetralogy of Fallot described in the
reports by Goldmuntz et al. (4) (n  114) and Benson et al. (2) (n  20) seven of
whom had NKX2.5 mutations.
Table 3. NKX2.5 Mutations Identified Among 608 Patients With Congenital Heart Disease
Mutation Site* Gene Region # Patients Type of Congenital Heart Defect
A44T (Lys15Ile) TN domain 1 Secundum atrial septal defect
G61C (Glu21Gln) 5 coding region 1 Tetralogy of Fallot
A65C (Gln22Pro) 5 coding region 1 Tetralogy of Fallot
C73T (Arg25Cys) 5 coding region 7 Tetralogy of Fallot (n  4†)
Truncus arteriosus (n  1)
Interrupted aortic arch (n  1)
Hypoplastic left heart syndrome (n  1)
C188T (Ala63Val) 5 coding region 1 L-transposition of the great arteries
C380A (Ala127Glu) 5 coding region 1 Secundum atrial septal defect
C646T (Arg216Cys) NK domain 1 Tetralogy of Fallot
C656T (Ala219Val) NK domain 1 Tetralogy of Fallot†
InsTCCCT701 (D235AFSter) 3 coding region 1 Secundum atrial septal defect
First-degree atrioventricular block
C823A (Pro275Thr) 3 coding region 1 Coarctation of the aorta
delAAC871 (del291Asn) 3 coding region 1 Double-outlet right ventricle
G967A (Ala323Thr) 3 coding region 1 Tetralogy of Fallot
*Numbering of nucleotides begins with the “A” of the ATG start codon as 1. †Two of the patients with tetralogy of Fallot and
an Arg25Cys mutation had pulmonary atresia, as did the patient with tetralogy of Fallot and an Ala219Val mutation; the other
four patients with tetralogy of Fallot and NKX2.5 mutations had pulmonary stenosis. Major aortopulmonary collateral arteries
were present in both patients with tetralogy of Fallot, pulmonary atresia, and an Arg25Cys mutation.
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D-transposition of the great arteries. Among patients with
conotruncal anomalies and an NKX2.5 mutation, the sid-
edness or branching pattern of the aortic arch was abnormal
in 6 of the 11 in whom the aortic arch anatomy was defined,
including 5 of the 9 mutation-positive patients with tetral-
ogy of Fallot and the mutation-positive patient with inter-
rupted aortic arch. Of 160 patients with left-sided lesions,
two were found to have mutations, including one with
hypoplastic left heart syndrome and one with coarctation of
the aorta and an intact ventricular septum. Mutations were
detected in 3 of 71 patients with a secundum ASD (4%),
and none of 7 with Ebstein’s malformation. None of the
mutation-positive patients had extracardiac anomalies or
syndromic features.
Eleven of the mutations were missense nucleotide sub-
stitutions (n  10) or in-frame deletions (n  1) predicted
to result in alteration or deletion of a single amino acid
residue, and one was a five-nucleotide insertion predicted to
cause premature termination of translation (Table 3). Four
of the mutations were located in (n  1) or immediately 3
to (n  3) the conserved amino-terminal TN domain; one
was midway between the TN domain and the homeodo-
main; one was located just 5 to the homeodomain; three
were located in (n  2) or immediately 3 to (n  1) the
conserved carboxy-terminal NK2 domain; and three were
located in the distal 3 coding region (Fig. 1). None of the
mutations were in the homeodomain. Abnormal AV con-
duction was identified in only one mutation-positive pa-
tient, who had first-degree AV block with a secundum ASD
and an insertion mutation in the 3 coding region predicted
to truncate the protein.
Sixteen of the 18 individuals with an NKX2.5 mutation
had no known family history of congenital heart disease
(although parents were not assessed for the presence of
occult cardiovascular anomalies in this study). The other
two were known to have at least one relative with a
cardiovascular defect, including a bileaflet aortic valve in the
grandfather of the patient with an Ala127Glu mutation and
secundum ASD, and a ventricular septal defect in the father
of a patient with an Arg25Cys mutation and tetralogy of
Fallot. The respective NKX2.5 mutations were carried by
both affected relatives. Of the 16 patients with no family
history of congenital heart disease, parental DNA was
available and evaluated for the corresponding mutation by
direct sequencing in six (Lys15Ile, Glu21Gln, Arg25Cys n
 2, Ala219Val, D235AFSter, del291Asn). In all six of
these cases, one parent carried the mutation, consistent with
decreased penetrance. Parental DNA was not available for
the remaining 10 patients with mutations.
The NKX2.5 gene was sequenced from the genomic
DNA of 50 random control subjects who were not known to
have congenital cardiovascular disease. None of the 12
mutations detected in our study patients were found in the
100 control chromosomes. Among the mutations identified
in our study population, the Arg25Cys mutation was found
in multiple subjects, whereas the other mutations were
unique. Five of the seven patients with an Arg25Cys
mutation in this series were of African-American ethnicity,
one was Hispanic, and one was Caucasian. This mutation
was identified in 2 of 43 (5%) African-American control
subjects, though it was not present in 100 chromosomes
from random control subjects, as previously described (4).
DISCUSSION
NKX2.5 is the earliest known marker of myocardial pro-
genitor cells in all species in which it has been studied
(7–10). Just as mutation of the Drosophila NKX2.5 ho-
molog, tinman, results in failure of heart formation (11,12),
homozygous inactivation of NKX2.5 in mammals results in
impaired cardiac looping and embryonic lethality (13,14).
Mice with a heterozygous cardiac-specific deletion of
NKX2.5 exhibit a more subtle phenotype, which consists of
atrial septal dysmorphogenesis, occasional abnormalities of
Figure 1. Diagram of the NKX2.5 gene, depicting the locations of new and previously reported mutations. Mutations identified in this report are noted
above the diagram of the gene, with the number of patients having the mutation noted. The arrows below the diagram indicate previously reported
mutations (1–3). Coding regions are indicated as hatched or white boxes, with the conserved TN domain (TN), homeodomain (HD), and NK2 domain
(NK) indicated by labeled white boxes. The 5 and 3 untranslated regions are depicted as smaller boxes, and the single intron as a broken line. The small
hearts indicate previously reported NKX2.5 mutations in which one or more affected individuals had structural cardiac anomalies other than a secundum
ASD. ASD  atrial septal defect; AVB  atrioventricular block; COA  coarctation of the aorta; DORV  double-outlet right ventricle; HLHS  hypoplastic
left heart syndrome; IAA  interrupted aortic arch; L-TGA  L-transposition of the great arteries; TA  truncus arteriosus; TOF  tetralogy of Fallot.
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the aortic valve, and, in females, prolongation of the PR
interval (15). Numerous studies have investigated the mech-
anisms of NKX2.5 regulation and its interaction with other
transcription factors thought to be important in early
cardiac development (14,16–21). Through these and other
studies, it has become clear that NKX2.5 plays a central role
in the determination of myocardial cell fate, and there is
evidence that it may be important during postnatal life as
well (22). Accordingly, there has been considerable interest
in the potential role of NKX2.5 in human cardiac develop-
ment and disease.
Based on our identification of NKX2.5 mutations in
individuals with isolated tetralogy of Fallot (4), we extended
our investigation to other conotruncal lesions. The indepen-
dent finding of an Arg25Cys mutation in an individual with
hypoplastic left heart syndrome provided the rationale to
extend the scope of our study to encompass prospectively
enrolled patients with left-sided lesions as well. The asso-
ciation of NKX2.5 mutations with secundum ASD and
tricuspid valve anomalies (2) prompted our prospective
evaluation of patients with sporadic secundum ASDs and
Ebstein’s malformation. In this report, we have detailed our
findings in these prospectively recruited cohorts of individ-
uals with primarily sporadic congenital cardiovascular
anomalies. Among 608 patients genotyped, 18 (3%) were
found to have an NKX2.5 mutation. Although NKX2.5
mutations were found in individuals with cardiovascular
anomalies of different types and categories (secundum ASD,
various conotruncal anomalies, and two left-sided lesions),
the most notable findings of this study are the frequency of
mutations in patients with secundum ASD (4%) and tetral-
ogy of Fallot (4%), and the absence of mutations in a
relatively large cohort of patients with D-transposition of
the great arteries.
Eleven of the 12 mutations found in this study were
unique. Only the Arg25Cys mutation was found in multiple
study patients (n  7). The significance of this mutation is
not clear, as has been discussed in a previous report (4).
Functional analysis of this mutation reported by Kasahara et
al. (23) showed normal nuclear localization and normal
binding of the mutant protein to monomeric DNA binding
sites, but a threefold higher concentration of mutant protein
was required for equally distributed binding to monomeric
and dimeric DNA binding sites, suggesting a slight impair-
ment of dimerization by the mutant NKX2.5. The effect of
this mutation on NKX2.5 function will require further
evaluation.
In the majority of previously reported patients with an
NKX2.5 mutation in conjunction with familial AV block
and a secundum ASD, the NKX2.5 mutation alters coding
sense in the homeodomain and/or is predicted to result in a
truncated protein (1–3). In contrast, all of the mutations
that we detected were in the 5 or 3 coding region of the
gene, with no homeodomain mutations. Only one patient
with an NKX2.5 mutation (the only patient with a truncat-
ing mutation in this series) had AV block. Experimental
studies have shown that the carboxy-terminal portion of
NKX2.5 is important in NKX2.5 function distinct from the
role of the homeodomain (23–25). Kasahara et al. found
this portion of the gene to be critical for the cooperative
homodimerization and heterodimerization (with other tran-
scription factors such as GATA4) of NKX2.5 protein on
dimeric DNA binding sites (24). In functional studies of the
previously reported NKX2.5 mutations, these authors dem-
onstrated decreased binding of mutant NKX2.5 proteins
with mutations outside the homeodomain to dimeric DNA
binding sites despite normal binding to monomeric sites
(23).
In addition, Schinke et al. (25) examined the effects of
cardiac-specific deletion of the NK2 domain of NKX2.5 in
mice. Null mutants died in utero at E14.5 and exhibited a
variety of structural cardiovascular anomalies, including
ventricular septal defect, double-outlet right ventricle, and
AV septal defect, as well as downregulation of the ventric-
ular markers Irx4 and MLC-2v, specifically in the right
ventricle. Heterozygous NK2 mutant mice, which survived
to term, also developed various structural cardiovascular
defects. Binding of the NK2 mutant protein to DNA was
not impaired, and mutant mice did not demonstrate AV
conduction abnormalities. These findings suggest that the
NK2 domain plays an important role in cardiovascular
development independent of the homeodomain.
Our finding of 12 distinct mutations in the 5 and 3
coding regions of NKX2.5 in 18 of 608 patients (3%) with
congenital cardiovascular anomalies, along with the afore-
mentioned experimental findings, suggests that NKX2.5
mutations outside of the homeodomain, either alone or in
conjunction with as-of-yet unidentified modifying factors,
may cause structural congenital cardiovascular anomalies
without affecting AV conduction. In 8 of the 16 patients
with an NKX2.5 mutation, a parental carrier was identified,
two of whom were known to have a congenital cardiovas-
cular anomaly. The finding of reduced phenotypic pen-
etrance associated with the NKX2.5 mutations identified in
this study is consistent with patterns frequently observed in
complex developmental anomalies and may indicate that
these mutations are associated with an increased risk of
congenital heart disease. We do not believe that the muta-
tions we have detected are random changes, insofar as they
were not detected among control subjects or patients with
certain diagnoses (e.g., D-transposition of the great arter-
ies). Further analysis of NKX2.5-mediated regulation of
cardiovascular development, as well as functional studies of
the mutations that have been identified, is necessary to
determine the mechanisms by which non-homeodomain
NKX2.5 mutations lead to congenital cardiovascular anom-
alies.
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